EXCLUSIVE: Nano-Cap TC BioPharm Concludes Initial Cohort B Patient Dosing In Mid-Stage Leukemia Trial, Data Readout By End Of 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2025
0mins
Source: Benzinga
Trial Progress: TC BioPharm announced that the first patient in Cohort B of the ACHIEVE Phase 2B trial for TCB008 in Acute Myeloid Leukemia has completed the full dosing regimen, with no drug-related adverse events reported so far.
Future Plans: The company aims to complete enrollment for the second cohort by mid-2025 and is also pursuing acquisition strategies to expand its therapeutic platform.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
